



Melanoma Research Foundation
Request for Proposals (RFP)
2022

RESEARCH OVERVIEW:

The Melanoma Research Foundation (MRF) is committed to advancing research across the spectrum of melanoma – from prevention through diagnosis, staging, treatment and survivorship. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges. Since 1998, the MRF has funded 242 innovative, high impact, basic, translational and clinical research projects. Further, in 2021, the MRF awarded over \$1,063,000 in *new* melanoma research. In 2022, the MRF will offer Established Investigator and Career Development Awards (as discussed in this RFP), as well as Medical Student Awards, Mid-Career Bridge Grants, and a Young Investigator Team Award to advance the field of translational immuno-oncology (detailed in separate RFPs as noted below).

Please visit www.melanoma.org for additional information on the MRF and to learn more about previously funded research. All questions or concerns regarding the MRF's Research Grant Program can be directed to the MRF Science Officer at research@melanoma.org or by calling 800-673-1290.

TYPES OF AWARDS OFFERED IN 2022:

Available through this award mechanism

Established Investigator Awards (EIA)

The EIAs provide funding of **up to \$100,000 per year for two years** to established melanoma researchers, or senior researchers working in closely related fields who wish to move into melanoma research.

Career Development Awards (CDA)

The CDAs provide funding of **up to \$50,000 per year for two years** to junior investigators. Researchers who are beginning a research career focused on melanoma are eligible. This year, in addition to general CDAs, the MRF will also offer specific career development awards focused on **COVID and Melanoma (COV CDA)** and **Women in Science (Silverstein Family Research Grant Challenge WIS CDA)**.

Available through separate award mechanisms *(please refer to the MRF website for additional details)*

Young Investigator Research Team Award

The MRF, through its Breakthrough Consortium (the MRFBC), is pleased to offer the MRFBC Young Investigator Research Team Award to advance the field of translational immuno-oncology (generously funded by a grant from Bristol-Myers Squibb (BMS)). This grant provides funding of **up to \$150,000 per year for two years** to an investigative team consisting of junior investigators and senior mentors. Application submissions are due by March 1st, 2022.

Mid-Career Bridge Grants

In response to a growing need in the field, the MRF has established its Mid-Career Bridge Grant to support investigators who are dedicated to melanoma research. This award will be for established researchers with pre-existing R01s, who have applied for a NIH R01 grant that was scored, but not funded. To support and sustain these investigators while they generate the data for the Response to Reviewers in the revised R01 (A1) submission, the MRF is offering bridge funding of **up to \$100,000 for one year**. Application submission deadlines are on April 15th, August 15th, or December 15th, 2022.

Medical Student Awards

The Medical Student Awards provide funding of **up to \$3,000 for one year** to medical students at accredited U.S. medical schools or institutions. These awards provide opportunities and funding for medical students to engage in short clinical or laboratory-based research projects focused on better understanding the biology and treatment of melanoma. 2022 applications are currently under review.

SPECIFIC TOPIC PROPOSALS (STPs):

The identification of scientific topics that address unmet clinical needs in melanoma research builds upon those identified through a 2019 meeting of multidisciplinary experts from the MRF's [Scientific Advisory Committee](#) and [Breakthrough Consortium](#), the results of which were published in Clinical Cancer Research ([PMID: 33414132](#)). As described in this manuscript, fundamental questions remain in the areas of prevention, tumor cell dormancy and metastasis, response/resistance to targeted and immune-based therapy, and melanoma and COVID-19. For 2022, these areas have been built upon to encompass the list below.

- ❖ ***Prevention and Population Science***
- ❖ ***Tumor Cell Dormancy and Metastasis***
- ❖ ***Therapy and Resistance***
- ❖ ***Melanoma and COVID-19 (a specific CDA to be awarded in this category as well)***

Applicants must clearly indicate which of the categories – if any – is being addressed in their application. Applications are not required to address these STPs, although those that do might be given extra consideration. However, in all cases, the scientific merit is the most important factor underlying the selection for funding.

ELIGIBILITY & REQUIREMENTS:

General (for all grant types)

- Applicants must hold a PhD or MD degree or equivalent at the time of the grant submission.
- For this RFP, applicants may be the PI or co-PI on only one submitted application.
- Applicants are eligible to respond to other MRF RFPs, as long as the research proposals are significantly different.
- American citizenship is not required. However, for all grants, the proposed research must be conducted in a non-profit research organization, a medical institution or an educational institution located in the United States.

- Applicants must show evidence of strong departmental or institutional support and commitment.
- PIs and co-PIs may not have an active research award with the MRF (please note: awards currently under no-cost extensions are not considered as active research awards).
- The use of relevant genetic models and/or human derived tumor samples is highly encouraged, but not required.
- Applicants may, but are not required to, submit applications focused on one of the STP unmet needs.
- Proposed research must comply with all applicable National Institutes of Health (NIH) animal and human welfare guidelines.
- Applicants are encouraged to discuss any eligibility questions with the MRF prior to applying.

Established Investigator Awards (EIAs)

- Applicants must have a title equivalent to Associate Professor or higher at the time of the grant submission. Both tenured and non-tenured track faculty are encouraged to apply.

Career Development Awards, including the COV and WIS CDAs

- Applicants who are postdoctoral fellows must have less than 5 years of postdoctoral experience at the time the grant will be awarded and must not have previously received any major grant support (e.g. from ACS, NIH, NCI, or DoD).
- Applicants who are not postdoctoral fellows may have a title of Research Associate/Scientist, Staff Scientist, Instructor, Assistant Professor, or equivalent at the time of the grant submission. For individuals in this category, previous grant support (e.g. K08, K99, K22, etc.) is allowed.
- For the COVID and Melanoma CDA (COV CDA), the proposed research must focus on COVID and melanoma.
- For the Silverstein Family Research Grant Challenge (WIS CDA), the applicant must identify as a woman.
- Applicants are required to have at least one mentor; their biosketch must be included in the application. Please note: mentors do not have to be at the applicant's own institution.

REVIEW PROCESS:

The MRF's Research Grant Program emphasizes basic, translational and clinical research projects that explore innovative approaches to understanding critical problems pertaining to prevention, diagnosis, staging and treatment of melanoma. All proposals will undergo rigorous peer review, where reviewers are selected based on their expertise in diverse areas of basic, translational and clinical melanoma research. Reviewers include members of the MRF's Scientific Advisory Committee (SAC), the Breakthrough Consortium (MRFBC), and the Community United for Research and Education of Ocular Melanoma (CURE OM), as well as members of the scientific and clinical melanoma community who are not in conflict with the application. Applications with the highest scores will be assessed by a panel of representatives from the initial review group. The top ranked grants are recommended for funding to the MRF Board of Directors. The number of grants selected for funding is determined by the MRF Board of Directors, based on available funds.

AWARD ADMINISTRATION AND REPORTING:

Award decisions will be made on or around **August 15th, 2022**. Upon acceptance of the award, the PI and the Institution will be required to sign an award letter accepting the MRF's terms and conditions.

Awards will cover research conducted over a two-year period. Funds are distributed two times each year, on or around September and March for a total of four payments over two years. A no-cost extension may be permitted with sufficient justification from the PI and approval from the Program Director. Requests for a no-cost extension must be made within 30 days of the award period expiration.

Interim financial and scientific progress reports are to be submitted to the MRF no later than 30 days prior to the end of the grant's first year. Final financial and scientific reports, detailing all activities during the award period, are to be submitted to the MRF within 60 days of the end of the award period (even if a no-cost extension is requested). The MRF may also request a short video explaining the importance of your work that can be used to educate the public.

Acknowledgment of support from the MRF must accompany any published report using data or findings from research conducted under an award from the MRF. The intellectual property reviewed remains solely within the institution.

STEP-BY-STEP APPLICATION INSTRUCTIONS:

The MRF will accept applications from January 10th – March 1st, 2022 for the 2022 award cycle. The deadline is March 1st, 2022 at 5 pm ET. All submissions, notifications and critiques will be completed entirely online through ProposalCENTRAL (<https://proposalcentral.altum.com/>).

Please read the instructions carefully prior to beginning the online grant submission process.

NOTE: Applications that represent resubmission of previously proposed studies, in whole or in part, may be submitted for consideration only twice; however, there is no restriction on the timing of the resubmissions. A one-page letter referencing the project title, a summary of changes to the application from the previous submission, and responses to reviewers' criticisms must be uploaded as an attachment during Step 12: Upload Attachments.

Step 1: Title Page

The project title should not exceed the space provided (75 characters, including spaces).

Choose the grant program, from the list noted below, to which you are applying (and if applicable, please select the appropriate STP category). You can only select one grant program; therefore, please select the most specialized grant for which you qualify. With respect to the CDAs, all grants will be considered for the General CDA pool (if not awarded one of the specialized grants).

- Established Investigator Award (EIA) – up to \$200,000 over a two-year period
- Career Development Awards (CDA) – up to \$100,000 over a two-year period – this includes general melanoma CDAs, the CDA focused on COVID and Melanoma (COV CDA) and the Silverstein Family Research Grant Challenge for Women in Science (WIS CDA)

The research period for all awards is a two-year period beginning September 30th, 2022 and ending September 29th, 2024.

Please specify if this is a new application or a resubmission.

Step 2: Enable Other Users to Access This Proposal

You have the option to allow other individuals access to your application. You can choose from three different levels of permission.

Step 3: Applicant/PI

Profile information is pre-loaded in this section. You may update your profile information here as well.

Step 4: Additional Applicant/PI Information

Additional applicant/PI information is requested in this section. All answers for this step are optional. This information will only be used for internal MRF purposes.

Step 5: Institution and Contacts

Institution information and contact information can be updated and/or changed here.

Step 6: Key Personnel

Key personnel, other than the applicant, who will provide support to the project, will be listed here. If this is a Career Development Award (CDA, COV CDA, or WIS CDA), the PI should also list their mentor in this section. A NIH Biosketch and Other Support Page (both active and pending) for all key personnel will be required to be uploaded in this section. The Other Support page must include information about all types of available research support (including direct costs and percent effort). Please note: with respect to the Other Support for CDA applications, there should be no funding overlap between the CDA applicant's proposed project and the mentor's funded research.

Step 7: Environment

Please provide a description of your institutional environment in which the research will be conducted. Please describe how this environment will contribute to the probability of success (e.g. institutional support, physical resources including laboratory, office space and common use facilities contributing to the proposed work, etc.). For all CDA applications, including the CDA, COV CDA, and WIS CDA grants, please also provide an overview of the institutional investment in the success of the investigator (e.g. travel, training, collegial support including the availability of organized peer groups, logistical support such as administrative management/oversight, and financial support such as protected time for research with salary support) as well as a description of your career goals/objectives including any career development/training activities that will occur during the grant period.

Step 8: Abstracts

Scientific Abstract

In the space provided, include a summary of the proposal that gives a brief description of the objectives, rationale, methods and expected results. The total length of the summary may not exceed 3,000 characters (including spaces) and should be written in scientific terms.

Lay Abstract

In the space provided, include a brief (<3,000 characters, including spaces) summary of the proposal. The lay level abstract needs to be written so that the everyday person can understand the significance, impact and innovation of the proposed research.

Keywords

Please select up to six appropriate keywords (from the list provided) that characterize the proposed research project.

If the project is awarded, portions of the abstracts may be used in the MRF's various publications, press releases, fundraisers and educational events.

Step 9: Budget Period Detail

Awards will be made for a two-year period. Please fill out the budget information for **both years**.

Please note for all grants:

- **Only direct costs are allowed.**
 - **Cost of living adjustments for personnel or non-personnel costs are not allowed.**
 - **When calculating salaries, please use actual costs – not the salary allowed by the NIH salary cap.**
- **Established Investigator Awards (EIA)**

Personnel Costs

All personnel may be named in this section. The salary and fringe benefits included in the budget is calculated based on total of salary and fringe benefits multiplied by the % effort. The MRF will consider up to 15% of the salary of the EIA recipient and/or any co-PIs; and up to 100% of the salary for a postdoctoral fellow, graduate student, and/ or technician.

Non-Personnel Costs

All budgeted expenses such as consumable supplies, animal costs, service fees and consultant fees must be itemized. Requests for major equipment will be closely scrutinized, should be carefully justified, and should not exceed 15% of the total (two year) budget. Indirect institutional costs are not allowed. Allowable travel expenses for meetings and research purposes – including to international meetings – are capped at \$2,000 per project year.

Established Investigator Awards will not exceed \$100,000 per year.

- **Career Development Awards (CDA), including the CDA focused on COVID and Melanoma (COV CDA) and the Silverstein Family Research Grant Challenge for Women in Science (WIS CDA)**

Personnel Costs

All personnel may be named in this section. The salary and fringe benefits included in the budget is calculated based on total of salary and fringe benefits multiplied by the % effort. The MRF will consider covering up to 50% of the salary for a CDA recipient. Mentors should not be salaried. Salaries for senior investigators, postdoctoral fellows, graduate students, and/or technicians can be included if they will contribute to the proposed aims and data to be obtained.

Non-Personnel Costs

All budgeted expenses such as consumable supplies, animal costs, service fees and consultant fees must be itemized. Requests for major equipment will be closely scrutinized, should be carefully justified, and should not exceed 15% of the total (two year) budget. Indirect institutional costs are not allowed. Allowable travel expenses for meetings and research purposes – including to international meetings – are capped at \$2,000 per project year.

Career Development Awards will not exceed \$50,000 per year.

Step 10: Budget Summary

This is a summary of the Budget Period Detail. Also, please give a brief justification for each budget item here.

Step 11: Organization Assurances

Information regarding human subjects, vertebrate animals, and/or recombinant DNA will be entered here (if relevant). If an application has just been submitted, please note that as well.

Step 12: Upload Attachments

All attachments must be in PDF form. Uploaded documents should fall under one of the following descriptions:

Letter of Support – A letter of support from your institution is required; additional letters of support are allowed. This letter should be from the department chair or other leader at the institution with direct knowledge of the applicant's value to the department and institution. A research laboratory head may write a letter of support for a postdoctoral fellow applicant; however, for all other CDA applicants, it is anticipated that the letter of support will come from a departmental chair or other institutional leader. The letter should also mention the trajectory of the candidate in terms of leadership within the department or institution.

Other – If the application is a resubmission of a previously proposed study, a summary of changes to the application from the previous submission, and responses to reviewers' criticisms must be uploaded here. This file must be limited to 1-page in length.

Research Plan – The research plan is limited to **6 pages, Arial font, at least 11pt font with ½ inch margins**. Single line spacing is acceptable. The text of the Research Plan should contain sufficient information for the evaluation by the reviewer panel and should cover:

1. Specific Aims (if the application addresses one or more STP, please cite the topic)
2. Background, rationale, and significance. Include a statement of significance of the proposed work, its clinical relevance to melanoma prevention, diagnosis and/or treatment, potential for further research and the potential for securing future funding for the project.
3. Preliminary Data: results of previous research related to the Project Title. Specify how the original research objectives have been met and include justification of support based on exceptional findings. If the original research objectives were not met or were modified, an explanation must be included.
4. Experimental design and procedures
5. References (References ARE NOT counted in the 6-page limit)

Step 13: Validate

Click the 'Validate' button here to check for any missing required information or files. All missing required information will be listed on the screen. Please correct any missing information before proceeding to the next step.

Step 14: Signature Page(s)

You may print the signature page(s) after you have completed all the proposal sections.

Step 15: Submit

Submit your application. You will be unable to submit if you have not provided all the required information. We encourage you to submit your application as early as possible so that we can assist you with any issues that may arise. **The deadline is March 1st, 2022 at 5 pm ET.**

FREQUENTLY ASKED QUESTIONS:

How do I apply for a grant?

The grant application will be available ONLY during the time applications are being accepted. During that time, you can apply for a research grant online at <http://proposalcentral.altum.com/>.

What is the deadline?

Applications will be accepted from January 10th – March 1st, 2022 at 5pm ET.

Do I need to be a U.S. citizen?

No. However, the proposed research must be conducted in a non-profit research organization, a medical institution or an educational institution located **in** the United States. Prior to submission, the interested PI should inquire for eligibility and obtain specific approval from the MRF Science Officer.

Am I eligible?

Please read all eligibility requirements. Should you have questions not answered here, please contact the MRF Science Officer at research@melanoma.org.

How many grant programs are currently funded by the foundation?

In 2022, the MRF will fund a total of 5 different grant programs: the MRFBC Young Investigator Team (up to \$300,000 over a two-year period), Established Investigator (up to \$200,000 over a two-year period), Career Development – including CDAs focused on COVID and melanoma and/or one for a woman in science (up to \$100,000 over a two-year period), Mid-Career Bridge Grants (up to \$100,000 over a one-year period), and Medical Student Awards (up to \$3,000 over a one-year period).

What is the difference between the programs?

The MRFBC Young Investigator Team Award is for junior investigators and mentors working as a team on immunotherapy research. The Established Investigator Awards are designed for senior researchers. The Mid-Career Bridge Grants are for established researchers with pre-existing R01s, who have applied for a NIH R01 grant that was scored, but not funded. The Career Development Awards (including the COV and WIS CDAs) are designed for junior researchers. The Medical Student Awards are designed for current medical students.

How long is the research plan section of the grant?

The research plan is limited to 6 pages, not including references.

What information is included in the project plan?

The text of the research plan should contain sufficient information for evaluation by the review panel. The plan should cover specific aims, background, rationale, significance, results of previous research directly related to the project title, experimental design and procedures and references. Please note: If the application is in response to a STP, the background section could be streamlined as the reviewers already realize the relevance/significance of the research.

Can an award be transferred to a new institution?

A grant can be transferred upon approval of the MRF Science Officer. The MRF envisions that for postdoctoral fellow CDA Awardees, whom may be transitioning to independent faculty positions, this may be a common occurrence. For detailed criteria and instructions, please contact the MRF Science Officer at research@melanoma.org.

Term	Definition
Key Personnel	The PI and other individuals who contribute to the scientific development or execution of a project in a substantive, measurable way, whether or not they receive salaries or compensation under the grant. Typically these individuals have doctoral or other professional degrees, although individuals at the masters or baccalaureate level may be considered key personnel if their involvement meets this definition. Consultants also may be considered key personnel if they meet this definition.
Principal Investigator (PI)	This is the grantee responsible for all activity being supported by the grant. He or she is responsible and accountable to the MRF for the proper conduct of the project or activity.
Other Support	Includes all financial resources, whether Federal, non-Federal, commercial or organizational, available in direct support of an individual's research endeavors, including, but not limited to, research grants, cooperative agreements, contracts, or organizational awards. Other support does not include training awards, start-up funds, prizes, or gifts.
Institutional Animal Care & Use Committee (IACUC)	Established at institutions in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals with broad responsibilities to oversee and evaluate the institutions' animal programs, procedures, and facilities. IACUC review and approval is required for all PHS supported activities involving live vertebrate animals prior to funding.
Institutional Review Board (IRB)	IRBs are set up by research institutions to ensure the protection of rights and welfare of human research subjects participating in research conducted under modifications in, or disapprove research protocols based on whether human subjects are adequately protected, as required by federal regulations and local institutional policy.
Clinical Trial	<p>A biomedical or behavioral research study of human subjects designed to answer specific questions about biomedical or behavioral interventions (drugs, treatments, devices, or new ways of using known drugs, treatments, or devices). Clinical trials are used to determine whether new biomedical or behavioral interventions are safe, efficacious, and effective. Clinical trials of an experimental drug, treatment, device, or intervention may proceed through four phases:</p> <ul style="list-style-type: none"> • Phase I: Testing in a small group of people (e.g. 20-80) to determine and evaluate safety (e.g. determines a safe dosage range and identify side effects). • Phase II: Study in a larger group of people (several hundred) to determine efficacy and further evaluate safety. • Phase III: Study to determine efficacy in large groups of people (from several hundred to several thousands) by comparing the intervention to other standard or experimental interventions, to monitor adverse effects, and to collect information to allow safe use. • Phase IV: Study done after the intervention has been marketed. These studies are designed to monitor the effectiveness of the approved intervention in the general population and to collect information about any adverse effects associated with widespread use.